Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bai'ai capsule is a Traditional Chinese Medicine (TCM) formulation developed by Yangtze River Pharmaceutical Group (specifically its subsidiary Beijing Haiyan Pharmaceutical) for the treatment of hypertension associated with metabolic syndrome. It is an oral botanical product, typically administered as a 0.5g capsule. Clinical research, including trials registered in the Chinese Clinical Trial Registry (e.g., ChiCTR-TRC-14004782), has evaluated its efficacy as an adjunctive therapy to standard antihypertensive agents like irbesartan. The drug is intended to improve blood pressure control and address metabolic disturbances in patients with metabolic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bai'ai capsule.